| Metric | Value | vs Q4 FY26 |
|---|---|---|
| Revenue | 386.00 Cr | 4.1% |
| Total Income | 394.25 Cr | 4.1% |
| Expenditure | 358.89 Cr | 6.6% |
| PBT | 35.36 Cr | 30.4% |
| Net Profit | 26.39 Cr | 34.4% |
| OPM | 11.02% | 2.01pp |
| NPM | 6.69% | 1.91pp |
| EPS | 5.67 | 11.4% |
Flat revenue masked by one-off gain; Q2 monsoon upside ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Management reaffirmed prior 15% growth + patented-led strategy; no new targets. Execution on 1-2 product launches/year on track. One-off land sale (₹5.7 Cr) temporarily inflated PAT.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered flat revenue (₹386 Cr, +2.4% YoY) and operational PAT (₹26.4 Cr including ₹5.7 Cr non-recurring land sale to promoter group). Headline PAT growth masked by one-off; core earnings likely flat YoY. Strategy sound—patented product roadmap (15% growth, 13-14% EBITDA target, doubling patented mix in 3 years) credible and R&D-backed—but execution early-stage. Key risk: export weakness (Brazil caution, logistics lag vs China) and cost pressures (employee increments, power, rupee -10-11%) offset margin expansion from mix shift.
₹386 Cr
Revenue · +2.4% YoY₹26.4 Cr
Reported PAT · +null% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Revenue remained broadly stable
OVERSTATED₹386 Cr vs ₹377 Cr Q1 FY26 (+2.4% YoY); down 4.1% QoQ from ₹402.5 Cr prior quarter
PAT increased 16% to ₹26.4 Cr
OVERSTATED16% growth is QoQ (vs ₹22.76 Cr in Q4), not YoY; stripped of ₹5.7 Cr land sale one-off, operational PAT flat YoY
Strong momentum in domestic business
METDomestic stable, export weak (10% of revenue), temporary RM constraints cited
Good growth in patented products PCT 410 and Fighter
METGaining scales/volumes in B2C, but still only 20-22% of B2C segment (hence ~10% of total revenue)
Earnings quality
What changed since the last call
Patent product traction accelerating
UpgradeLaunched PCT 410, Fighter gaining scales/volumes in Q1 with strong B2B co-marketing uptake. Aim to double patented share in 3 years (from 20-22% to 40-50% of B2C).
Export segment weakness
DowngradeBrazil demand softer (geopolitical volatility, customer holdback, China logistics advantage), temporary RM constraints. 10% of revenue vs prior guidance aspiration for growth.
Cost inflation pressure rises
DowngradeEmployee costs up (annual increments), power/fuel up (coal rates), raw material volatility from geopolitics and 10-11% rupee depreciation. Time lag to pass through in B2C.
Capacity headroom confirmed
NeutralTechnical utilization 70-75% (scope to grow), formulation 25-30% (designed for peak season). Multi-product plants allow high-value low-volume swaps for new patented launches.
Monsoon trajectory improving
UpgradeQ1 hit by El Nino/geopolitical caution; July 2026 monsoon now supportive, acreage green across cotton/soybean/chillies. Management expects strong Q2 momentum.
The Q&A
Analysts pressed hard on Q1 softness (revenue flat, PAT one-off inflation via land sale), Brazil risks, and cost headwinds. Management held firm on strategy (patented roadmap, market share), acknowledged macro headwinds (rupee, geopolitical, RM volatility), but confident on H2 Kharif uptick. Deflected PAT split by business (common costs). Tone: cautious but resolute.
Product mix evolution — Kareena Jain, individual investor
AnsweredCurrent: B2C branded 45%, B2B 45%, export 10%. Formulation 75%, technical 25%. Patented products 20-22% of B2C; aiming to double in 3 years.
IPO proceeds deployment — Aniket Redkar, individual investor
AnsweredLoan repayment complete. Small amount pending brokerage settlement (2-3 months). IPO account closure imminent.
Raw material, margin outlook — Aniket Redkar, individual investor
AnsweredVolatility from geopolitics and rupee depreciation (-10-11%) offset by product mix shift. Inventory covers cost lag in B2C; B2B passes through to customers.
International demand, Brazil strategy — Aniket Redkar, individual investor
AnsweredBrazil cautious (liquidity issues, credit challenges, China logistics advantage). Focusing on established B2B customers. Expanding to Argentina/Uruguay with second-tier distributors.
Kharif season assessment — Aniket Redkar, individual investor
AnsweredQ1 hit by El Nino caution. July monsoon now good, acreage up (cotton, soybean, chillies, paddy stable). Insect pressure will benefit GSP's insecticide/fungicide strength. Q2 expected strong.
Patented product opportunity — Krisha Jain, Palada Family Office
AnsweredIntroduced 12 products in 3 years; no saturation expected next 3-4 years. Target: double patented share in 2-3 years. Expanding to herbicides and potato (gap segments).
Capacity utilization headroom — Krisha Jain, Palada Family Office
AnsweredTechnical 70-75% (scope to grow); multi-product plants allow high-value/low-volume swaps. Formulation 25-30% (designed for peak season, not bottleneck).
Strategic direction formulations vs brands — Anirudh Sharma, Ekaant Investments
AnsweredYes, formulation focus. B2C branded main goal, supported by B2B (filling portfolio gaps with patented formulations). Market share 3-3.5%, targeting 7-8%.
Farmer behavior shifts — Anirudh Sharma, Ekaant Investments
AnsweredFarmers increasingly aware (West Bengal example), adopting specialty chemicals, moving toward preventive spraying (like developed markets). New generation more digitally connected.
R&D pipeline and product launches — Shravan Modi, Syndicate Family Office
AnsweredTechnical R&D: 1-2 new products/year for next 5 years (4-5 year data generation cycle). Formulation R&D: 2-3 patented formulations/year for next 4-5 years. Pipeline robust.
International market focus and pipeline — Shravan Modi, Syndicate Family Office
AnsweredPrimary focus: Latin America (Brazil, USA), reverse season to India allows 12-month plant utilization. Secondary: Africa, Asia. Volume/value focus on LatAm.
Competitive differentiation in patented formulations — Priya Thakkar, individual investor
AnsweredThree differentiators: (1) newer technical molecules getting off-patent, (2) holistic farmer solutions via field trials, (3) innovative formulations (SE, ZC, OD). First-mover advantage on off-patent technicals.
Midterm growth targets and milestones — Priya Thakkar, individual investor
AnsweredRevenue: ~15% growth; EBITDA: 13-14% margin in next 2-3 years. Milestones: patented mix doubling, market share 7-8%, new product launches, capacity utilization.
PAT split by business; margin drivers — Ayushi, individual investor
PartialPAT segmentation difficult due to common costs. Margin expansion from patented products in B2C and good B2B margins. PAT upside also from reduced interest cost.
Other income one-off, run rate — Ayushi, individual investor
Answered₹5.7 Cr from land sale to promoter (66,000 sqm for ₹23 Cr approved). No other land sales planned. One-off; expect lower other income run rate going forward.
Q2 season shape and material constraints — Ayushi, individual investor
AnsweredMaterial supply now clear (not constraint). Monsoon July supportive covering major part. On track to achieve anticipated growth. South India (AP/Tel/KA) under watch on monsoon.
B2B/B2C domestic mix evolution — Maira Mittal, individual investor
AnsweredDomestic 80%, export 20%. B2B and B2C currently ~40% each. 3-year target: B2C 45-50%, B2B 30-35%, export ~20%.
Guidance
~15% revenue growth expected medium-term
MediumDriven by patented product mix shift (targeting 40-50% of B2C in 3 years) and market share expansion (3-3.5% to 7-8%).
EBITDA margin 13-14% in next 2-3 years
MediumUplift from mix shift to patented products (higher margin) and interest cost reduction post-IPO debt repayment.
Risks the call surfaced
Export demand softness
MediumBrazil (largest export market) facing demand caution, liquidity/credit constraints, and China logistics advantage. Temporary supply constraints in H1 causing delays and order losses.
Raw material cost inflation
MediumGeopolitical volatility (petrochemical linkage), 10-11% rupee depreciation, and coal rate increases pushing RM prices higher. Time lag to pass through to B2C customers; B2B can pass through.
Employee cost inflation
LowAnnual wage increments and slight headcount increase in Q1 pressuring margins. Partially offset by gross margin expansion but reduces bottom-line upside.
Patented product execution risk
MediumCore strategy hinges on delivering 1-2 new technical molecules/year and 2-3 new patented formulations/year for 4-5 years. Regulatory delays, field trial failures, or farmer adoption shortfalls could derail mix expansion from 20-22% to 40-50% in 3 years.
Seasonal concentration and monsoon risk
MediumBusiness is Kharif-led (Q2 represents ~60% of annual PAT). Poor monsoon, pest cycles, or farmer sentiment shifts could materially impact annual performance.
One-off land sale inflating earnings
High₹5.7 Cr land sale to promoter-group Indo-GSP represents 22% of reported Q1 PAT. Operational earnings flat YoY; headline growth misleading without disclosure.
Import dependency
LowCompany relies on imports for some technical molecules; backward integration underway but not yet complete. Geopolitical supply shocks could disrupt sourcing.
Management
Score 7/10. Clear on strategy (patented roadmap, R&D pipeline, market share expansion) and transparent on headwinds (Brazil caution, cost inflation, RM volatility). Some deflection on PAT segmentation by business (cited common costs); land sale one-off disclosed. Candid on Kharif seasonality. Confidence justified by executed launches but needs to prove 15% growth target. Track record solid on R&D (12 products in 3 years, on pace for 1-2/year). Launched PCT 410, Fighter scaling well. IPO loan repayment complete on schedule. Rating upgrade to A+/A1 by ICRA validates performance. Revenue growth (2.4% YoY) lags 15% guidance; execution gap to close.
1 · Q2 FY27 (Jul-Sep 2026)
Peak Kharif monsoon, acreage growth (cotton +, soybean +, chillies +), insect pressure driving demand
2 · H2 FY27 (Oct 2026+)
Brazil season ramp (reverse of India Kharif), export revenue uptick, latent demand destocking
3 · FY27-FY29
R&D pipeline: 1-2 technical products/year, 2-3 patented formulations/year; herbicide and potato products targeting
Key risk: export weakness (Brazil caution, logistics lag vs China) and cost pressures (employee increments, power, rupee -10-11%) offset margin expansion from mix shift.
Patented strategy on track; one-off masks flat operations
Q1 reported PAT hit ₹26.4 crore, but a ₹5.7 crore land sale to the promoter group inflated the number by a fifth. Strip it out: operational earnings flat year-on-year. The long-term strategy is sound; near-term execution lags guidance.
₹26.4 Cr
announced on earnings call
₹5.7 Cr
to promoter Indo-GSP (66,000 sqm)
₹20.7 Cr
flat YoY; the real earnings
On the surface, Q1 PAT jumped to ₹26.4 crore. But dig into the call and a different story emerges: the company sold 66,000 square metres of land to a promoter-linked entity (Indo-GSP) for an approved value of ₹23 crore, recognising a ₹5.7 crore gain on the transaction. That one-off item swallows 22% of reported PAT. Operational earnings — the business running day-to-day — came in at ₹20.7 crore, essentially flat year-on-year. That's the core number to anchor on.
Revenue stumbled, but it's Q1
Revenue of ₹386 crore was up 2.4% year-on-year from ₹377 crore in Q1 FY26, but the growth is nominal and the quarter-on-quarter trend is softer: ₹386 crore is down 4.1% from the prior quarter's ₹402.5 crore. Q1 is an off-peak season for GSP — Kharif sowing has just begun, export demand is soft (especially Brazil, where geopolitical caution and credit constraints have dampened customer buying), and temporary raw material logistics constraints slowed shipments. Management flagged that July 2026 monsoon came better than Q1's El Niño-weakened forecast, setting up Q2 (which the company says drives ~60% of annual PAT) as the critical quarter to watch.
Revenue remained broadly stable
Overstated₹386 Cr vs ₹377 Cr YoY (+2.4%); down 4.1% QoQ from ₹402.5 Cr
PAT increased 16% to ₹26.4 Cr
Overstated16% is QoQ vs ₹22.76 Cr in Q4; YoY comparison is flat after stripping ₹5.7 Cr land sale
Strong momentum in domestic business
SupportedDomestic 80% stable; export 10% weak (Brazil caution, China logistics loss, RM constraints)
Good growth in patented products PCT 410 and Fighter
SupportedScaling volumes in B2C but still only 20–22% of B2C segment (~10% of total revenue)
What changed on this call
Patented product traction confirmed. PCT 410 and Fighter are gaining scale and volume in B2C; B2B co-marketing partnerships accelerating adoption. Management reaffirmed the target to double patented product share in B2C from today's 20–22% to 40–50% within three years.
Export weakness deepened. Brazil (largest export market) facing demand caution due to geopolitical volatility, customer liquidity pressures, and competitive disadvantage vs. China's logistics model. Management is shifting focus to established B2B customers and expanding into Argentina and Uruguay with second-tier distributors; destocking expected until September.
Cost inflation pressure rising. Employee annual increments, power/fuel cost increases, and 10–11% rupee depreciation are pushing raw material costs higher. Inventory is buffering the B2C lag in cost pass-through, but margins face risk if geopolitical volatility persists.
Capacity headroom confirmed. Technical production is running at 70–75% utilization (scope to grow); formulation capacity at 25–30% (designed for peak season, not a bottleneck). Multi-product plants allow high-value, low-volume swaps for new patented launches.
Monsoon trajectory improving. Q1 was hit by El Niño caution. July 2026 monsoon is now supportive, with acreage rising across cotton, soybean, chillies, and stable paddy. Insect pressure is building — a tailwind for GSP's insecticide and fungicide strength. Management expects strong Q2 momentum.
The strategy is sound; execution must prove it
Management reaffirmed its three-year guidance: ~15% revenue growth, 13–14% EBITDA margins, and patented products scaling to 40–50% of B2C revenue. The R&D pipeline is real — 1–2 new technical products per year and 2–3 new patented formulations per year, confirmed for the next 4–5 years. The company has launched 12 products in the past three years, and ICRA upgraded its rating to A+ (long-term) and A1 (short-term) on loan repayment completion and demonstrated execution. The long-term story — shifting from generic formulation play to a patented, high-margin innovation platform — is credible.
The catch: Q1 revenue growth of 2.4% lags the 15% target by six times. Operational earnings were flat despite headlines of momentum. The company is betting that Q2 Kharif uptick, monsoon acreage expansion, and accelerating patented product adoption will close this gap. But the market is now watching execution, not strategy.
The bull-bear ledger
Green. Patented product roadmap is on track; 12 launches in 3 years, pipeline confirmed for next 4–5 years. R&D-backed market share expansion from 3–3.5% to 7–8% is a genuine long-term opportunity. Gross margin improved 240 basis points via product mix; multi-product plants allow agile scaling.
Red. Reported PAT is inflated 22% by a one-off land sale; operational earnings flat YoY. Revenue growth (2.4%) vs guidance (15%) is a six-fold miss. Export segment (10% of revenue) is weak with near-term headwinds (Brazil, China competition). Cost inflation (rupee −10–11%, employee increments, power) has time-lag pass-through risk in B2C.
Yellow. Monsoon-led business means Q2 (Kharif peak) is 60% of annual PAT; a poor monsoon or pest cycle would derail the year. Patented product execution risk: must prove 40–50% mix expansion in 3 years amid competitive pressure. Import dependency (for some technical molecules) exposed to geopolitical supply shocks, though backward integration is underway.
Ranked risks — what should concern a holder
One-off land sale inflates earnings quality
High₹5.7 Cr represents 22% of reported PAT. Operational earnings are flat YoY; without this one-off, headline growth narrative collapses. Timing of sale (April 2026 approval, Q1 recognition) to promoter-linked entity raises optics near peak valuation.
Revenue growth execution gap widens
High2.4% YoY growth vs 15% guidance target. If Q2 doesn't deliver strong Kharif momentum, full-year guidance will likely miss. Cost inflation headwinds and export weakness compound this risk.
Export demand weakness (Brazil caution, China competition)
Medium10% of revenue is export; Brazil (largest market) is soft on geopolitical volatility and customer liquidity. China's logistics advantage is causing order loss. Destocking expected until September; recovery timing uncertain.
Cost inflation pressure on margins
MediumRupee −10–11% YTD, employee increments, power/fuel costs rising. Inventory buffering B2C lag, but if geopolitics persist, pass-through lag could compress margins. B2B can pass through but may lose volume.
Patented product execution and farmer adoption
MediumCore strategy assumes 40–50% revenue mix from patented products in 3 years. Regulatory delays, field trial failures, or weak farmer adoption would derail guidance. Current 20–22% mix shows early traction but not proven at scale.
Seasonal concentration and monsoon risk
MediumQ2 (Kharif) represents ~60% of annual PAT. Poor monsoon, pest cycles, or crop failures would materially impact full-year. El Niño caution in Q1 already dampened demand; July monsoon recovery is critical.
How the market is positioned — and what it says about the stock
Price action post-result. The stock fell 0.88% on day 1 after the announcement (from the ₹594 pre-result close), delivering at 80.8% volume. By day 3, it recovered +0.38%, suggesting partial rebound on strategy confidence. However, the initial selloff is telling: the market digested the one-off land sale and flat operational earnings, and decided to trim positions rather than add on the dip.
Valuation and drawdown context. The stock is at ₹589.75 (as of Aug 17, 2026), down just 2.97% from its all-time high of ₹607.8, but up 60.26% from its 52-week low of ₹368. RSI stands at 74.1 — overbought territory — leaving limited room for near-term upside and elevated downside risk if sentiment shifts or earnings miss.
Institutional flows. FII ownership dropped 2.35 percentage points quarter-on-quarter (from 11.54% in Q4 FY26 to 9.19% in Q1 FY27). DII ownership fell 2.59 percentage points (from 2.96% to 0.37%). Both domestic and foreign institutions are trimming, likely on the execution gap and overbought technicals. Promoter holding remains steady at 71.73% — no insider selling at highs, but also no insider buying on weakness.
The market's two-handed message: the strategy is credible, but near-term execution is soft, valuation is frothy, and institutions are exiting on both fronts. This is a wait-and-see setup heading into Q2.
1 · Q2 revenue growth (the execution barometer)
Must show >5% YoY to credibly path to 15% full-year guidance. Kharif acreage is rising; monsoon July supportive; insect pressure building (GSP strength). Miss here and guidance reprieve is off the table.
2 · Patented product mix evolution and volume scaling
Track % of B2C revenue from patented products (currently 20–22%); watch volumes for PCT 410 and Fighter. B2B co-marketing momentum will signal farmer adoption velocity. 3-year target of 40–50% credible only if quarterly progression is visible.
3 · Export recovery and Brazil stabilization
Brazil demand, order flow, and destocking timeline. If China competition persists or liquidity crises deepen, LatAm strategy pivots (Argentina/Uruguay expansion) will take time. Watch for revenue recovery in H2.
GSP Crop Science is a steady execution play with genuine long-term upside — not a step-change story. The one-off land sale is a distraction from the real metric: operational earnings of ₹20.7 crore, flat year-on-year. Revenue growth of 2.4% vs guidance of 15% is the core debate. The company has a track record (12 product launches in 3 years), R&D pipeline (confirmed for 4–5 years), and addressable opportunity (market share from 3–3.5% to 7–8%); management tone was cautious but resolute. But the market is overbought (RSI 74.1), institutions are exiting (FII/DII trim), and near-term catalysts hinge on Q2 Kharif uptick.
The number to monitor from here: Q2 revenue growth. If it confirms >5% YoY and patented volumes accelerate, the strategy remains on track and 15% full-year guidance is plausible. If Kharif disappoints or costs compress margins further, execution risk rises sharply and downside risk is material. For now, this is a Hold — waiting for Q2 to prove the strategy or expose the execution gap.